Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Regulation FD Disclosure

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Regulation FD Disclosure
Item 7.01

Story continues below

Bellerophon Therapeutics, Inc. (the "Company") issued a press release on May 8, 2018, to announce that the Company has reached agreement with the US Food and Drug Administration on all key aspects of its planned Phase 2b study of INOpulse® for the treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease (PH-COPD).

A copy of this press release is attached hereto as Exhibit 99.1. The information included in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:


Bellerophon Therapeutics, Inc. Exhibit
EX-99.1 2 a8-kmay2018copdex991.htm EXHIBIT 99.1 Exhibit Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary DiseaseWarren,…
To view the full exhibit click here

About Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.

An ad to help with our costs